LENZ Therapeutics, Inc.
LENZ
$28.88
$0.3651.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 71.59% | 126.98% | 219.27% | 142.30% | 264.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.07% | -34.84% | -4.06% | 27.52% | 173.79% |
| Operating Income | 39.07% | 34.84% | 4.06% | -27.52% | -173.79% |
| Income Before Tax | 47.00% | 45.90% | 30.37% | -31.40% | -161.57% |
| Income Tax Expenses | 100.56% | -- | -- | -- | -159.08% |
| Earnings from Continuing Operations | 46.60% | 45.90% | 30.37% | -31.40% | -151.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.60% | 45.90% | 30.37% | -31.40% | -151.27% |
| EBIT | 39.07% | 34.84% | 4.06% | -27.52% | -173.79% |
| EBITDA | 39.16% | 34.87% | 4.15% | -27.51% | -173.84% |
| EPS Basic | 96.18% | 96.09% | 94.68% | 45.67% | -1,119.03% |
| Normalized Basic EPS | 96.21% | 96.09% | 94.68% | 45.67% | -1,169.09% |
| EPS Diluted | 96.18% | 96.09% | 94.68% | 45.67% | -1,119.03% |
| Normalized Diluted EPS | 96.21% | 96.09% | 94.68% | 45.67% | -1,169.09% |
| Average Basic Shares Outstanding | 1,297.34% | 1,285.07% | 1,209.10% | 141.84% | -79.39% |
| Average Diluted Shares Outstanding | 1,297.34% | 1,285.07% | 1,209.10% | 141.84% | -79.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |